Scancell Hldgs Plc (SCLP) - Cash Flow Conversion Efficiency

Latest as of October 2025: 0.846x

Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has a cash flow conversion efficiency ratio of 0.846x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.08 Million ≈ $-861.55 USD) by net assets (GBX-8.37 Million ≈ $-1.02K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scancell Hldgs Plc (SCLP) net asset quality to measure how much of total assets are equity-financed.

Scancell Hldgs Plc - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Scancell Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Scancell Hldgs Plc (SCLP) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Scancell Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scancell Hldgs Plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Team Internet Group PLC
LSE:TIG
0.091x
InsuraGuest Technologies Inc
V:ISGI
0.216x
Surya Oil & Gas Corp.
NASDAQ:SURY
0.011x
Baroyeca Gold & Silver Inc
V:BGS
0.194x
ARC MINERALS LTD
F:DFYA
N/A
Enersize Oy
ST:ENERS
0.057x
Sagalio Energy Ltd
AU:SAN
-0.002x
GLOBAL HELIUM CORP.
F:5P0
N/A

Annual Cash Flow Conversion Efficiency for Scancell Hldgs Plc (2009–2025)

The table below shows the annual cash flow conversion efficiency of Scancell Hldgs Plc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Scancell Hldgs Plc.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-04-30 GBX-3.83 Million
≈ $-466.61
GBX-6.11 Million
≈ $-742.92
1.592x -64.36%
2024-04-30 GBX-3.50 Million
≈ $-426.46
GBX-15.66 Million
≈ $-1.91K
4.468x +242.12%
2023-04-30 GBX-6.23 Million
≈ $-758.38
GBX-8.14 Million
≈ $-990.40
1.306x +426.11%
2022-04-30 GBX19.48 Million
≈ $2.37K
GBX-7.80 Million
≈ $-949.40
-0.400x +60.75%
2021-04-30 GBX7.65 Million
≈ $930.54
GBX-7.80 Million
≈ $-949.40
-1.020x -35.45%
2020-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.03 Million
≈ $-855.71
-0.753x -0.21%
2019-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.02 Million
≈ $-853.88
-0.752x -157.92%
2018-04-30 GBX13.94 Million
≈ $1.70K
GBX-4.06 Million
≈ $-494.32
-0.291x +50.77%
2017-04-30 GBX6.50 Million
≈ $790.78
GBX-3.85 Million
≈ $-468.13
-0.592x -153.79%
2016-04-30 GBX9.99 Million
≈ $1.22K
GBX-2.33 Million
≈ $-283.58
-0.233x +40.30%
2015-04-30 GBX6.75 Million
≈ $821.77
GBX-2.64 Million
≈ $-321.06
-0.391x -69.41%
2014-04-30 GBX9.08 Million
≈ $1.10K
GBX-2.09 Million
≈ $-254.70
-0.231x +41.23%
2013-04-30 GBX5.09 Million
≈ $619.57
GBX-2.00 Million
≈ $-243.14
-0.392x -418.26%
2012-04-30 GBX6.97 Million
≈ $848.21
GBX859.62K
≈ $104.59
0.123x +132.17%
2011-04-30 GBX4.64 Million
≈ $564.07
GBX-1.78 Million
≈ $-216.21
-0.383x -76.43%
2010-04-30 GBX6.05 Million
≈ $735.87
GBX-1.31 Million
≈ $-159.88
-0.217x -7.79%
2009-04-30 GBX5.25 Million
≈ $639.26
GBX-1.06 Million
≈ $-128.85
-0.202x --

About Scancell Hldgs Plc

LSE:SCLP UK Biotechnology
Market Cap
$1.23 Million
GBX10.11 Billion GBX
Market Cap Rank
#30425 Global
#772 in UK
Share Price
GBX9.74
Change (1 day)
-1.62%
52-Week Range
GBX8.54 - GBX26.50
All Time High
GBX27.50
About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more